Towards medication-enhancement of cognitive interventions in schizophrenia

Handbook of Experimental Pharmacology

Volumn 213, Issue , 2012, Pages 81-111

  Chou, Hsun Hua ^a   Twamley, Elizabeth ^a   Swerdlow, Neal R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; Cognitive remediation; Cognitive therapy; Cognitive training; Neurocognition; Schizophrenia

Indexed keywords

AMANTADINE; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; BROMOCRIPTINE; CATECHOLAMINE DERIVATIVE; CLOZAPINE; CYCLOSERINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MEMANTINE; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NICOTINE; PERGOLIDE; PHENCYCLIDINE; PLACEBO; POMAGLUMETAD METHIONIL; PRAMIPEXOLE; QUETIAPINE; TOLCAPONE; N METHYLASPARTIC ACID;

ADD ON THERAPY; AGORAPHOBIA; ARTICLE; COGNITION; COGNITIVE THERAPY; DRUG EFFECT; DRUG SENSITIVITY; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; MENTAL PATIENT; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYMPTOM; UNSPECIFIED SIDE EFFECT; COGNITIVE DEFECT; DRUG ANTAGONISM; ELECTROENCEPHALOGRAPHY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; REVIEW;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; HUMANS; N-METHYLASPARTATE; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84868312783     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25758-2_4     Document Type: Article

References (174)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767 (Pubitemid 28252654)
2. Akil M, Pierri JN, Whitehead RE, Edger CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589 (Pubitemid 29459991)
3. Aparacio-Legarza MI, Cutts AJ, Davis B, Reynolds GP (1997) Deficits in [3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci Lett 232:13-16 (Pubitemid 27382108)
4. Barch DM (2010) Pharmacological strategies for enhancing cognition in schizophrenia. In: Swerdlow N (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience, vol 4. Springer, Heidelberg, pp 43-96
5. Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43-58 (Pubitemid 40957060)
6. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, Phelps ME (1992) Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 49:681-689
7. Becker DR, Drake RE, Bond GR, Xie H, Dain BJ, Harrison K (1998) Job terminations among persons with severe mental illness participating in supported employment. Commun Ment Health J 34:71-82 (Pubitemid 28177705)
8. Benes FM (2010) Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology 35:239-257
9. Benkert O, Müller-Siecheneder F, Wetzel H (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5(Suppl):43-53 (Pubitemid 26017259)
10. Bitsios P, Giakoumaki SG, Theou K, Frangou S (2006) Increased prepulse inhibition of the acoustic startle response is associated with better strategy formation and execution times in healthy males. Neuropsychologia 44:2494-2499 (Pubitemid 44062565)
11. Brabban A, Tai S, Turkington D (2009) Predictors of outcome in brief cognitive behavior therapy for schizophrenia. Schizophr Bull 35:859-864
12. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343 (Pubitemid 9016401)
13. Brown GG, Thompson WK (2010) Functional brain imaging in schizophrenia: Selected results and methods. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 181-214
14. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT (2007) The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164:1593-1602 (Pubitemid 350069740)
15. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2011) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later? Schizophr Bull 37:1209-1017
16. Clark CR, Geffen GM, Geffen LB (1986) Role of monoamine pathways in the control of attention: effects of droperidol and methylphenidate on normal adult humans. Psychopharmacology 90:28-34 (Pubitemid 16075157)
17. Cruz DA, Weaver CL, Lovallo EM, Melchitzky DS, Lewis DA (2009) Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34:2112-2124
18. Davis M, Ressler K, Rothbaum BO, Richardson R (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60:369-375 (Pubitemid 44215855)
19. de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW, Toni I (2008) Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 131:2172-2180. doi:10.1093/brain/awn140
20. de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS (2009) Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 70:1416-1423
21. Dean B, Boer S, Gibbons A, Money T, Scarr E (2009) Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry 22:154-160
22. Demily C, Franck N (2008) Cognitive remediation: a promising tool for the treatment of schizophrenia. Expert Rev Neurother 8:1029-1036 (Pubitemid 351962071)
23. Dick DM, Riley B, Kendler KS (2010) Nature and nurture in neuropsychiatric genetics: where do we stand? Dialogues Clin Neurosci 12:7-23
24. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378:180-182
25. Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, Keshavan MS (2009) Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 60:1468-1476
26. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psycho-pharmacology 131:196-206 (Pubitemid 27261609)
27. Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET (2011) Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berl) 214:779-789
28. Fiszdon JM, Cardenas AS, Bryson GJ, Bell MD (2005) Predictors of remediation success on a trained memory task. J Nerv Ment Dis 193:602-608. doi:10.1097/01.nmd.0000177790.23311.ba (Pubitemid 41298362)
29. Fiszdon JM, Choi J, Bryson GJ, Bell MD (2006) Impact of intellectual status on response to cognitive task training in patients with schizophrenia. Schizophr Res 87:261-269. doi:10.1016/ j.schres.2006.04.011 (Pubitemid 44467852)
30. Fleming K, Bigelow LB, Weinberger DR, Goldberg TE (1995) Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 31:357-362
31. Fox K (2009) Experience-dependent plasticity mechanisms for neural rehabilitation in somato-sensory cortex. Philos Trans R Soc Lond Series B Biol Sci 364:369-381. doi:10.1098/ rstb.2008.0252
32. Giakoumaki SG, Bitsios P, Frangou S (2006) The level of prepulse inhibition in healthy individuals may index cortical modulation of early information processing. Brain Res 1078:168-170
33. Giakoumaki SG, Roussos P, Bitsios P (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33:3058-3068
34. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628-1630 (Pubitemid 26406177)
35. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27 (Pubitemid 29055046)
36. Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27:582-589 (Pubitemid 351339444)
37. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF (2008) Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 106:320-327
38. Golimbet VE, Alfimova MV, Gritsenko IK, Ebstein RP (2007) Relationship between dopamine system genes and extraversion and novelty seeking. Neurosci Behav Physiol 37:601-606 (Pubitemid 47322131)
39. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC (2011) D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 131:69-74
40. Granholm E, McQuaid JR, McClure FS, Link PC, Perivoliotis D, Gottlieb JD, Patterson TL, Jeste DV (2007) Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. J Clin Psychiatry 68:730-737 (Pubitemid 46841856)
41. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT (2012) Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 69:121-127
42. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330 (Pubitemid 26074706)
43. Green MF (2007) Cognition, drug treatment, and functional outcome in schizophrenia: A tale of two transitions. Am J Psychiatry 164:992-994 (Pubitemid 47121382)
44. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119-136 (Pubitemid 30317696)
45. Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41-51. doi:10.1016/j. schres.2004.09.009 (Pubitemid 39452904)
46. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012) Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One 7(1):e29630
47. Grillon C, Ameli R, Charney DS, Krystal J, Braff D (1992) Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 32:939-943 (Pubitemid 23024906)
48. Gur RE, Keshavan MS, Lawrie SM (2007) Deconstructing psychosis with human brain imaging. Schizophr Bull 33:921-931 (Pubitemid 47216648)
49. Hasenkamp W, Kelley M, Egan G, Green A, Wilcox L, Boshoven W, Lewison B, Duncan E (2011) Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjects. Psychiatry Res 187:324-328
50. Haasio K (2010) Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 95:163-189
51. Haut KM, Lim KO, MacDonald A (2010) Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization and specificity. Neuropsychopharmacology 35:1850-1859
52. Heckers S, Konradi C (2010) Hippocampal pathology in schizophrenia. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 529-553
53. Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, Alpert NM (1998) Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1:318-323
54. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-445 (Pubitemid 28323862)
55. Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA, Lahti AC (2010) Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35:632-640
56. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S (2009) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15:2550-2559
57. Jones RW (2010) A review comparing the safety and tolerability of memantine with the acetyl-cholinesterase inhibitors. Int J Geriatr Psychiatry 25:547-553
58. Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, Pfolz H (1997) Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol 7:65-70
59. Kawakubo Y, Kasai K (2006) Support for an association between mismatch negativity and social functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 30:1367-1368 (Pubitemid 44216056)
60. Kawakubo Y, Kamio S, Nose T, Iwanami A, Nakagome K, Fukuda M, Kato N, Rogers MA, Kasai K (2007) Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. Psychiatry Res 152:261-265 (Pubitemid 47214643)
61. Keefe RSE and Harvey PD (2012) Cognitive impairment in schizophrenia. In: Geyer MA and Gross G (ed), Novel anti-schizophrenia treatments. Handbook of experimental pharmacology
62. Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M (2011a) Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. doi:10.1093/schbul/ sbr153
63. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011b) Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125:161-168
64. Keller TA, Just MA (2009) Altering cortical connectivity: remediation-induced changes in the white matter of poor readers. Neuron 64:624-631. doi:10.1016/j.neuron.2009.10.018
65. Kelly JT, Abuzzahab FS Sr (1971) The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharmacol New Drugs 11:211-214
66. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR (2008) The MATRICS consensus cognitive battery: part 2. Co-norming and standardization. Am J Psychiatry 165:214-220
67. Keshavan MS, Eack SM, Wojtalik JA, Prasad KM, Francis AN, Bhojraj TS, Greenwald DP, Hogarty SS (2011) A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia. Schizophr Res 130:123-129
68. Kessler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355-371 (Pubitemid 32983509)
69. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024-1031
70. Kim YW, Shin JC, An YS (2010) Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. Ann Nuclei Med 24:363-369
71. Kimberg DY, D'Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 41:1020-1027 (Pubitemid 36349393)
72. Kimberg DY, D'Esposito M, Farah MJ (1997) Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport 8:381-385
73. Kirrane RM, Mitropoulou V, Nunn M, New AS, Harvey PD, Schopick F, Silverman J, Siever LJ (2000) Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 22:14-18
74. Klingberg S, Wittorf A, Herrlich J, Wiedemann G, Meisner C, Buchkremer G, Frommann N, Wölwer W (2009) Cognitive behavioural treatment of negative symptoms in schizophrenia patients: study design of the TONES study, feasibility and safety of treatment. Eur Arch Psychiatry Clin Neurosci 259:S149-S154
75. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104 (Pubitemid 24362365)
76. Korosi A, Baram TZ (2009) The pathways from mother's love to baby's future. Front Behav Neurosci 3:27. doi:10.3389/neuro.08.027.2009
77. Korostenskaja M, Nikulin VV, Kicić D, Nikulina AV, Kähkönen S (2007) Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull 72:275-283 (Pubitemid 46602746)
78. Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T (2008) Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Eur Neuropsychopharmacol 18:117-121 (Pubitemid 350296846)
79. Kumari V, Soni W, Sharma T (1999) Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156:1046-1051 (Pubitemid 29302798)
80. Kumari V, Gray JA, Geyer MA, ffytche D, Soni W, Mitterschiffthaler MT, Vythelingum GN, Simmons A, Williams SC, Sharma T (2003) Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res 122:99-113 (Pubitemid 36511394)
81. Kumari V, Peters ER, Fannon D, Antonova E, Premkumar P, Anilkumar AP, Williams SC, Kuipers E (2009) Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia. Biol Psychiatry 66:594-602
82. Kumari V, Premkumar P, Fannon D, Aasen I, Raghuvanshi S, Anilkumar AP, Antonova E, Peters ER, Kuipers E (2012) Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis. Schizophr Res 134:232-238
83. Kunugi H, Tanaka M, Hori H, Hashimoto R, Saitoh O, Hironaka N (2007) Prepulse inhibition of acoustic startle in Japanese patients with chronic schizophrenia. Neurosci Res 59:23-28 (Pubitemid 47285391)
84. Kurtz MM, Moberg PJ, Gur RC, Gur RE (2001) Approaches to cognitive remediation of neuro-psychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol Rev 11:197-210 (Pubitemid 33744613)
85. Kurtz MM, Wexler BE, Fujimoto M, Shagan DS, Seltzer JC (2008) Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. Schizophr Res 102:303-311. doi:10.1016/j. schres.2008.03.023
86. Kurtz MM, Seltzer JC, Fujimoto M, Shagan DS, Wexler BE (2009) Predictors of change in life skills in schizophrenia after cognitive remediation. Schizophr Res 107:267-274
87. Kvajo M, McKellar H, Joseph A, Gogos JA (2010) Molecules, signaling and schizophrenia. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 629-656
88. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211-221
89. Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, Siegel SJ (2010) Ketamine modulates theta and gamma oscillations. J Cogn Neurosci 22:1452-1464
90. Lee T, Seeman P (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 137:191-197 (Pubitemid 10143768)
91. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429-447
92. Levitt JJ, Bobrow L, Lucia D, Srinivasan P (2010) A selective review of volumetric and morphometric imaging in schizophrenia. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 243-282
93. Lewis DA, Hashimoto T, Morris HM (2008) Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotox Res 14:237-248
94. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223 (Pubitemid 41345943)
95. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A, MEM-MD-29 Study Group (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322-1329
96. Light GA, Braff DL (2005a) Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry 162:1741-1743 (Pubitemid 41318247)
97. Light GA, Braff DL (2005b) Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62:127-136 (Pubitemid 40189128)
98. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL (2006) Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 60:1231-1240 (Pubitemid 44693537)
99. Light GA, Braff DL, Sprock J, Cadenhead KS, Swerdlow NR (2007a) Prepulse inhibition of startle is positively associated with higher order cognition in women. Abstr Soc Neuroscience 806:17
100. Light GA, Swerdlow NR, Braff DL (2007b) Preattentive sensory processing is associated with cognitive and psychosocial functioning in healthy adults. J Cog Neurosci 19:1624-1632 (Pubitemid 47547865)
101. Linn GS, Javitt DC (2001) Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12:117-120 (Pubitemid 32099039)
102. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160-170
103. Luciana M, Collins PF (1997) Dopamine modulates working memory for spatial but not object cues in normal humans. J Cogn Neurosci 4:58-68
104. Luciana M, Depue RA, Arbisi P, Leon A (1992) Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cogn Neurosci 4:58-68
105. Luciana M, Collins PF, Depue RA (1998) Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 8:218-226 (Pubitemid 28226157)
106. Lynch D, Laws KR, McKenna PJ (2010) Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med 40:9-24
107. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensori-motor gating in the rat. Neuropsychopharmacology 2:229-308
108. Marder SR, Buchanan RW (2009) Pharmacological strategies to improve cognition in schizophrenia: results from TURNS and MATRICS-CT. American College of Neuropsychophar-macology (ACNP), Hollywood, FL
109. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12:268-275
110. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100:6186-6191 (Pubitemid 36576952)
111. McGurk SR, Meltzer HY (2000) The role of cognition in vocational functioning in schizophrenia. Schizophr Res 45:175-184
112. McGurk SR, Mueser KT (2004) Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model. Schizophr Res 70:147-173 (Pubitemid 39141095)
113. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (2007a) Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry 164:437-441. doi:10.1176/appi.ajp. 164.3.437 (Pubitemid 46513157)
114. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007b) A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164:1791-1802 (Pubitemid 351739231)
115. McGurk SR, Mueser KT, DeRosa TJ, Wolfe R (2009) Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophr Bull 35:319-335
116. Medalia A, Choi J (2009) Cognitive remediation in schizophrenia. Neuropsychol Rev 19:353-364
117. Medalia A, Richardson R (2005) What predicts a good response to cognitive remediation interventions? Schizophr Bull 31:942-953. doi:10.1093/schbul/sbi045 (Pubitemid 41437789)
118. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000) Methylpheni-date enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20:1-6
119. Mehta MA, Swainson R, Gogilvie AD, Sahakian BJ, Robbins TW (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers. Psychopharmacology 159:10-20 (Pubitemid 34031245)
120. Mueser KT, Bellack AS, Douglas MS, Wade JH (1991) Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. Psychiatry Res 37:281-296
121. Müller U, von Cramon Y, Pollmann S (1998) D1-versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18:2720-2728 (Pubitemid 28141817)
122. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS consensus cognitive battery: part 1. Test selection, reliability, and validity. Am J Psychiatry 165:203-213
123. Parnas AS, Weber M, Richardson R (2005) Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 83:224-231 (Pubitemid 40488810)
124. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107 (Pubitemid 47517511)
125. Penn DL, Meyer PS, Evans E, Wirth RJ, Cai K, Burchinal M (2009) A randomized controlled trial of group cognitive-behavioral therapy vs. enhanced supportive therapy for auditory hallucinations. Schizophr Res 109:52-59
126. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, Orbach G, Morgan C (2002) Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 32:783-791
127. Porto PR, Oliveira L, Mari J, Volchan E, Figueira I, Ventura P (2009) Does cognitive behavioral therapy change the brain? A systematic review of neuroimaging in anxiety disorders. J Neuropsychiatry Clin Neurosci 21:114-125. doi:10.1176/appi.neuropsych.21.2.114
128. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994) Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257:7-12 (Pubitemid 24178543)
129. Quednow BB, Wagner M, Mössner R, Maier W, Kühn KU (2010) Sensorimotor gating of schizophrenia patients depends on catechol O-Methyltransferase Val158Met polymorphism. Schizophr Bull 36:341-346
130. Reichenberg A, Harvey PD (2007) Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull 133:833-858. doi:10.1037/ 0033-2909.133.5.833
131. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136-1144 (Pubitemid 39463415)
132. Rice DP (2009) The economic impact of schizophrenia. J Clin Psychiatry 60(Suppl 1):4-6, discussion 28-30
133. Roberts RC, Roche JK, Conley RR, Lahti AC (2009) Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 63:520-530
134. Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 9:275-308 (Pubitemid 37254706)
135. Roussos P, Giakoumaki SG, Bitsios P (2009) Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O- methyltransferase rs4818c/g polymorphism. Biol Psychiatry 66:997-1004
136. Saxena S, Gorbis E, O'Neill J, Baker SK, Mandelkern MA, Maidment KM, Chang S, Salamon N, Brody AL, Schwartz JM, London ED (2009) Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry 14:197-205. doi:10.1038/sj.mp. 4002134
137. Schwartz JM, Stoessel PW, Baxter LR, Martin KM, Phelps ME (1996) Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 53:109-113 (Pubitemid 26049387)
138. Sellwood W, Wittkowski A, Tarrier N, Barrowclough C (2007) Needs-based cognitive-behavioural family intervention for patients suffering from schizophrenia: 5-year follow-up of a randomized controlled effectiveness trial. Acta Psychiatr Scand 116:447-452 (Pubitemid 350086148)
139. Siegel BV, Trestman RL, O'Faithbheartaigh S, Mitropoulou V, Amin F, Kirrane R, Silverman J, Schmeidler J, Keefe RS, Siever LJ (1996) D-Amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr Res 20:29-32
140. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ (1995) A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176-179
141. Sweet RA, Bergen SE, Sun Z, Marcsisin MJ, Sampson AR, Lewis DA (2007) Anatomical evidence of impaired feedforward auditory processing in schizophrenia. Biol Psychiatry 61:854-864 (Pubitemid 46412274)
142. Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA (2009) Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 34:374-389
143. Swerdlow NR (1996) Cortico-striatal substrates of cognitive, motor and sensory gating: Speculations and implications for psychological function and dysfunction. In: Panksepp J (ed) Advances in biological psychiatry, vol 2. JAI, Greenwich, CT, pp 179-208
144. Swerdlow NR (2011) Are we studying and treating schizophrenia correctly? Schizophr Res 130:1-10
145. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156:194-215 (Pubitemid 32702213)
146. Swerdlow NR, Stephany N, Shoemaker JM, Ross L, Wasserman LC, Talledo J, Auerbach PP (2002) Effects of amantadine and bromocriptine on startle and sensorimotor gating: Parametric studies and cross-species comparisons. Psychopharmacology 164:82-92 (Pubitemid 35203845)
147. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006a) Startle gating deficits in a large cohort of patients with schizophrenia: Relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63:1325-1335 (Pubitemid 44878517)
148. Swerdlow NR, Talledo J, Sutherland AN, Nagy D, Shoemaker JM (2006b) Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology 31:2011-2021
149. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199:331-388
150. Swerdlow NR, Lelham SA, Sutherland Owens AN, Chang WL, Sassen SDT, Talledo JA (2009a) Pramipexole effects on startle gating in rats and normal men. Psychopharmacology 205:689-698
151. Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J (2009b) The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34:1854-1864
152. Swerdlow NR, Light GA, Thanam S, Slater A, Talledo JA (2010) Memantine and amphetamine effects on neurocognition and sensorimotor gating in healthy subjects. Abstract, American College of Neuropsychopharmacology (ACNP), December 5-9
153. Swerdlow NR, Talledo JA, Kei J, Thanam S, Lamb SN, Light GA (2011) Amphetamine effects on MATRICS performance in healthy adults: Prelude to a genetic analysis. Abstract, American College of Neuropsychopharmacology (ACNP), December 4-8
154. Tai S, Turkington D (2009) The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. Schizophr Bull 35:865-873
155. Talledo JA, Sutherland Owens AN, Schortinghuis T, Swerdlow NR (2009) Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology 204:165-175
156. Taub E, Uswatte G, Elbert T (2002) New treatments in neurorehabilitation founded on basic research. Nat Rev Neurosci 3:228-236 (Pubitemid 135706592)
157. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007) Neurophysio-logical endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33:69-94 (Pubitemid 46026260)
158. Twamley EW, Narvaez JM, Becker DR, Bartels SJ, Jeste DV (2008a) Supported employment for middle-aged and older people with schizophrenia. Am J Psychiatr Rehabil 11:76-89 (Pubitemid 351323438)
159. Twamley EW, Savla GN, Zurhellen CH, Heaton RK, Jeste DV (2008b) Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil 11:144-163 (Pubitemid 351507794)
160. Twamley EW, Burton CZ, Vella L (2011) Compensatory cognitive training for psychosis: who benefits? Who stays in treatment? Schizophr Bull 37(Suppl 2):S55-S62. doi:10.1093/schbul/ sbr059
161. Uhlhaas PJ, Singer W (2006) Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52:155-168 (Pubitemid 44466360)
162. Urban N, Abi-Dargham A (2010) Neurochemical imaging in schizophrenia. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 215-242
163. van der Linden D, Massar SA, Schellekens AF, Ellenbroek BA, Verkes RJ (2006) Disrupted sensorimotor gating due to mental fatigue: preliminary evidence. Int J Psychophysiol 62:168-174 (Pubitemid 44307374)
164. Volk DW, Lewis DA (2010) Prefrontal cortical circuits in schizophrenia. In: Swerdlow NR (ed) Behavioral neurobiology of schizophrenia and its treatment. Current topics in behavioral neuroscience. Springer, Heidelberg, pp 485-508
165. Vollenweider FX, Barro M, Csomor PA, Feldon J (2006) Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry 60:597-603 (Pubitemid 44402382)
166. Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H, Kaiser WA, Sauer H (1999) Decreased frontal activation in schizophrenics during stimulation with the Continuous Performance Test - a functional magnetic resonance imaging study. Eur Psychiatry 14:17-24
167. Weike AI, Bauer U, Hamm AO (2000) Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry 47:61-70 (Pubitemid 30016081)
168. Willenborg B, Schmoller A, Caspary J, Melchert UH, Scholand-Engler HG, Jauch-Chara K, Hohagen F, Schweiger U, Oltmanns KM (2011) Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects. J Clin Endocrinol Metab 96: E384-E388
169. Wong D, Wagner H, Tune L, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563 (Pubitemid 17125279)
170. Wonodi I, Cassady SL, Adami H, Avila M, Thaker GK (2006) Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality. Psychiatry Res 141:237-245
171. Wykes T, Sturt E, Katz R (1990) The prediction of rehabilitative success after three years. The use of social, symptom and cognitive variables. Br J Psychiatry 157:865-870
172. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P (2011) A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 168:472-485. doi:10.1176/appi.ajp. 2010.10060855
173. Wynn JK, Sugar C, Horan WP, Kern R, Green MF (2010) Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol Psychiatry 67:940-947
174. Zdanys K, Tampi RR (2008) A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32:1362-1374 (Pubitemid 352033662)